OptiNose Inc (OPTN) Given Consensus Rating of “Strong Buy” by Analysts
OptiNose Inc (NASDAQ:OPTN) has received an average broker rating score of 1.25 (Strong Buy) from the four analysts that cover the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a buy rating and three have given a strong buy rating to the company. OptiNose’s rating score has improved by 6% in the last 90 days as a result of a number of analysts’ ratings changes.
Brokers have set a one year consensus target price of $29.25 for the company and are predicting that the company will post ($0.46) EPS for the current quarter, according to Zacks. Zacks has also given OptiNose an industry rank of 202 out of 265 based on the ratings given to its competitors.
Separately, Piper Jaffray Companies set a $28.00 price target on shares of OptiNose and gave the stock a “buy” rating in a research report on Monday, January 15th.
Several institutional investors have recently added to or reduced their stakes in the company. Macquarie Group Ltd. acquired a new position in shares of OptiNose during the 4th quarter worth about $512,000. Millennium Management LLC acquired a new position in shares of OptiNose during the 4th quarter worth about $190,000. TIAA CREF Investment Management LLC acquired a new position in shares of OptiNose during the 4th quarter worth about $173,000. Teachers Advisors LLC acquired a new position in shares of OptiNose during the 4th quarter worth about $184,000. Finally, California State Teachers Retirement System acquired a new position in shares of OptiNose during the 4th quarter worth about $162,000. Institutional investors own 29.53% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another domain, it was illegally copied and reposted in violation of US & international copyright & trademark law. The correct version of this report can be accessed at https://www.thecerbatgem.com/2018/03/14/optinose-inc-optn-given-consensus-rating-of-strong-buy-by-analysts.html.
OptiNose Company Profile
OptiNose, Inc is a pharmaceutical company. The Company is focused on the development and commercialization of products for patients treated by ear, nose and throat, or ENT, and allergy specialists. The Company’s products candidates include XHANCE (Nasal Polyps), XHANCE (Chornic Sinusitis) OPN-300, OPN-021, and other.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.